Main Article Content

Dr. Sidra Shah
Dr Muhammad Sannan
Dr Talal Safdar
Dr Adeela Kosar Bajwa
Dr Arshad Ali
Dr Mahboob Ur Rehman


Atherosclerotic Cardiovascular Disease, Diabetes, LDL, HDL


Objectives:To assess the effectiveness of Lipid therapy in lowering atherosclerotic cardiovascular disease (ASCVD) risk in Diabetic individuals

Materials and Methods:  This prospective cohort study was conducted at Department of Medicine, Khyber Teaching Hospital, Peshawar from July, 2023 to December, 2023 in which a total of 99 patients were enrolled after fulfilling the inclusion criteria. 5 ml blood was taken from all the patients and sent for lipid profile tests to check total cholesterol, LDL, HDL, and Tg. All the patients were then prescribed Statin therapy. All the patients were followed after 6 month of treatment to see the incidence of atherosclerotic cardiovascular disease (ASCVD).

Results: In this study, 99 patients, with a mean age of 51.64±12.52 years, were enrolled. Prior to treatment, the mean levels of LDL, HDL, and triglycerides were 114.42±9.96 mg/dL, 43.46±6.71 mg/dL, and 129.66±22.09 mg/dL, respectively. The mean HbA1C (%) value was 8.05±0.96. Among our study participants, 8 individuals (8.1%) experienced ASCVD. There is week positive correlation between ASCVD and LDL cholesterol, HDL cholesterol and Triglycerides in DM patients with statin medication after 6 month.

Conclusion: The study's findings concluded that people with a high risk of heart disease could see benefits from using statins. Further studies was recommended in order to see the effect of statin in lowering LDL cholesterol more clearly.

Abstract 90 | PDF Downloads 38


1. Henning RJ. Type-2 diabetes mellitus and cardiovascular disease. Future cardiology. 2018;14(6):491-509.
2. Kinoshita M, Yokote K, Arai H, Iida M, Ishigaki Y, Ishibashi S, et al. Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2017. Journal of atherosclerosis and thrombosis. 2018;25(9):846-984.
3. Rosenzweig JL, Bakris GL, Berglund LF, Hivert M-F, Horton ES, Kalyani RR, et al. Primary prevention of ASCVD and T2DM in patients at metabolic risk: an Endocrine Society clinical practice guideline. The Journal of Clinical Endocrinology & Metabolism. 2019;104(9):3939-85.
4. Vesa CM, Popa L, Popa AR, Rus M, Zaha AA, Bungau S, et al. Current data regarding the relationship between type 2 diabetes mellitus and cardiovascular risk factors. Diagnostics. 2020;10(5):314.
5. Amelia R, Sari Wahyuni A, Yunanda Y, Wijaya H. Atherosclerotic Cardiovascular Disease in Diabetes Patients. Current Diabetes Reviews. 2023;19(8):62-9.
6. Glovaci D, Fan W, Wong ND. Epidemiology of diabetes mellitus and cardiovascular disease. Current cardiology reports. 2019;21:1-8.
7. Cusi K. The epidemic of type 2 diabetes mellitus: its links to obesity, insulin resistance, and lipotoxicity. Diabetes and exercise. 2009:3-54.
8. Aynalem SB, Zeleke AJ. Prevalence of diabetes mellitus and its risk factors among individuals aged 15 years and above in Mizan-Aman town, Southwest Ethiopia, 2016: a cross sectional study. International journal of endocrinology. 2018;2018.
9. Federation I. IDF Diabetes Atlas, 9th edn. 2019.
10. Garber AJ, Handelsman Y, Grunberger G, Einhorn D, Abrahamson MJ, Barzilay JI, et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm–2020 executive summary. Endocrine Practice. 2020;26(1):107-39.
11. Butool I, Nazir S, Afridi M, Shah SM. Evaluation and assessment of prescribing patterns in elderly patients using two explicit criteria based screening tools:(The PRISCUS list and STOPP/START criteria). Pakistan journal of medical sciences. 2018;34(6):1357.
12. Care D. Standards of medical care in diabetes 2019. Diabetes Care. 2019;42(Suppl 1):S124-38.
13. Chapman MJ, Zamorano JL, Parhofer KG. Reducing residual cardiovascular risk in Europe: Therapeutic implications of European medicines agency approval of icosapent ethyl/eicosapentaenoic acid. Pharmacology & therapeutics. 2022;237:108172.
14. Rosenblit PD. Extreme atherosclerotic cardiovascular disease (ASCVD) risk recognition. Current diabetes reports. 2019;19:1-20.
15. Committee ADAPP, Committee: ADAPP. 10. Cardiovascular disease and risk management: Standards of Medical Care in Diabetes—2022. Diabetes care. 2022;45(Supplement_1):S144-S74.
16. Jagpal A, Navarro-Millán I. Cardiovascular co-morbidity in patients with rheumatoid arthritis: a narrative review of risk factors, cardiovascular risk assessment and treatment. BMC rheumatology. 2018;2(1):1-14.
17. Khalid MR, Lakho MA, Zubair M, Bhutto A, Abbas S, Yousif A. Correlation of lipid profile in diabetes patients: The potential for risk reducing of atherosclerotic cardiovascular disease.
18. Jayakumari C, Jabbar PK, Soumya S, Jayakumar R, Das DV, Girivishnu G, et al. Lipid profile in Indian patients with type 2 diabetes: the scope for atherosclerotic cardiovascular disease risk reduction. Diabetes Spectrum. 2020;33(4):299-306.
19. Ravnskov U, de Lorgeril M, Diamond DM, Hama R, Hamazaki T, Hammarskjöld B, et al. LDL-C does not cause cardiovascular disease: a comprehensive review of the current literature. Expert review of clinical pharmacology. 2018.